<code id='2A3B83E793'></code><style id='2A3B83E793'></style>
    • <acronym id='2A3B83E793'></acronym>
      <center id='2A3B83E793'><center id='2A3B83E793'><tfoot id='2A3B83E793'></tfoot></center><abbr id='2A3B83E793'><dir id='2A3B83E793'><tfoot id='2A3B83E793'></tfoot><noframes id='2A3B83E793'>

    • <optgroup id='2A3B83E793'><strike id='2A3B83E793'><sup id='2A3B83E793'></sup></strike><code id='2A3B83E793'></code></optgroup>
        1. <b id='2A3B83E793'><label id='2A3B83E793'><select id='2A3B83E793'><dt id='2A3B83E793'><span id='2A3B83E793'></span></dt></select></label></b><u id='2A3B83E793'></u>
          <i id='2A3B83E793'><strike id='2A3B83E793'><tt id='2A3B83E793'><pre id='2A3B83E793'></pre></tt></strike></i>

          explore

          explore

          author:knowledge    Page View:49299
          A clipboard with checklist on blue dark background. -- health tech coverage from STAT
          Adobe

          A Pittsburgh artificial intelligence startup emerging as a challenger to Microsoft’s clinical note taking business has raised $150 million, a rare mega deal in a funding lull. The startup, Abridge, also has an unlikely cheerleader: Paul Ricci, the former head of Nuance, the service from Microsoft it competes with.

          Abridge sells an AI tool that rapidly transcribes and summarizes doctors’ conversations with patients in a hospital’s electronic health records software. The startup’s leaders and investors tell STAT they’re betting that their medical knowledge, agility, and willingness to co-develop features with customers makes it a more attractive long term option than Nuance, which Microsoft says is currently used by most U.S. hospitals.

          advertisement

          Microsoft, Abridge and other startups like Suki, Corti and Nabla are locked in a race to ease provider burnout by automating clinical note taking, and — thanks to generative AI — organizing the data in a way that could improve care, such as suggesting topics for follow-up, simplifying billing or analyzing trends at the broader patient population level.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more
          Merck, Johnson & Johnson CEOs will testify on high drug prices
          Merck, Johnson & Johnson CEOs will testify on high drug prices

          Johnson&JohnsonCEOJoaquinDuatoMICHAELBUHOLZER/AFPviaGettyImagesWASHINGTON—MerckCEORobertDavisand

          read more
          At least 13 dead in Texas as scorching temps continue
          At least 13 dead in Texas as scorching temps continue

          1:17FirefighterEMTWilliamDorseyandfirefighterEMTRodrigoPinedatreatamigrantwomansufferingfromheatexha

          read more

          Merck, Johnson & Johnson CEOs will testify on high drug prices

          Johnson&JohnsonCEOJoaquinDuatoMICHAELBUHOLZER/AFPviaGettyImagesWASHINGTON—MerckCEORobertDavisand